DK2865663T3 - Hidtil ukendte indansulfamidderivater - Google Patents
Hidtil ukendte indansulfamidderivater Download PDFInfo
- Publication number
- DK2865663T3 DK2865663T3 DK13807707.8T DK13807707T DK2865663T3 DK 2865663 T3 DK2865663 T3 DK 2865663T3 DK 13807707 T DK13807707 T DK 13807707T DK 2865663 T3 DK2865663 T3 DK 2865663T3
- Authority
- DK
- Denmark
- Prior art keywords
- inden
- mmol
- dihydro
- sulfamide
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids
- C07C307/08—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (9)
1. Forbindelse eller farmaceutisk acceptabelt salt deraf, som er valgt fra følgende gruppe: 1) N-[(lS)-2,2,5,7-tetrafluor-2,3-dihydro-lH-inden-l-yl]sulfamid, 2) N-[(IS)-2,2,4,7-tetrafluor-2,3-dihydro-lH-inden-l-yl]sulfamid, 3) (+)-N-(2,2,4,6,7-pentafluor-2,3-dihydro-lH-inden-l-yl)sulfamid, 4) N-[(IS*)-5-cyano-2,2-difluor-7-methyl-2,3-dihydro-lH-inden-1-yl]sulfamid, 5) (-)-N-(7-chlor-2,2,5-trifluor-2,3-dihydro-lH-inden-l- yl)sulfamid, 6) (-)-N-(7-chlor-2,2,4-trifluor-2,3-dihydro-lH-inden-l-yl)sulfamid, 7) (-)-N- (7-chlor-2,2-difluor-2,3-dihydro-lH-inden-l-yl)sulfamid, 8) (-)-N- (7-chlor-2,2,6-trifluor-2,3-dihydro-lH-inden-l-yl)sulfamid, 9) ( + )-N- (5-chlor-2,2,7-trifluor-2,3-dihydro-lH-inden-l-yl)sulfamid, 10) N-[(IS)-2,2-difluor-7-methyl-2,3-dihydro-lH-inden-l-yl]sulfamid, 11) N-[(IS)-2,2,5-trifluor-7-methyl-2,3-dihydro-lH-inden-l-yl]sulfamid, 12) N-[(IS*)-2,2,4-trifluor-7-methyl-2,3-dihydro-lH-inden-l-yl]sulfamid, 13) N-[(IS*)-7-(difluormethyl)-2,2-difluor-2,3-dihydro-lH-inden-l-yl]sulfamid, 14) N-[(IR*,2R*)-2,4,7-trifluor-2,3-dihydro-lH-inden-l-yl]sulfamid, 15) (-)-N-[(IR*,2R*)-7-chlor-2,4-difluor-2,3-dihydro-lH-inden-1-yl]sulfamid, 16) (+)-N-[(IR*,2R*)-7-chlor-2,4-difluor-2,3-dihydro-lH-inden-1-yl]sulfamid, 17) (-)-N-[(IR*,2R*)-7-chlor-2,5-difluor-2,3-dihydro-lH-inden-1-yl]sulfamid, 18) (+)-N-[(IR*,2R*)-4-chlor-7-fluor-2-methoxy-2,3-dihydro-1H-inden-l-yl]-sulfamid, 19) (+)-N-(7-chlor-4-fluor-2,3-dihydro-lH-inden-l-yl)sulfamid, 20) (±)-N-(5-fluor-7-methyl-2,3-dihydro-lH-inden-l-yl)sulfamid, 21) (-)-N-(4-fluor-7-methyl-2,3-dihydro-lH-inden-l- yl)sulfamid, 22) ( + )-N-(4 — fluor-7-methyl-2,3-dihydro-lH-inden-l-yl)sulfamid, 23) (+)-N-(7-methyl-2,3-dihydro-lH-inden-l-yl)sulfamid, 24) (+)-N-(5-chlor-7-methyl-2,3-dihydro-lH-inden-l-yl)sulfamid, 25) (-)-N-(4-chlor-7-fluor-2,3-dihydro-lH-inden-l-yl)sulfamid, 2 6) ( + )-N-(7-chlor-5-cyano-2,3-dihydro-IH-inden-1-yl)sulfamid, 27) (-)-N-(7-chlor-5-cyano-2,3-dihydro-lH-inden-l-yl)sulfamid, 28) (-)-N-(5-chlor-7-fluor-2,3-dihydro-IH-inden-1-yl)sulfamid, 29) N-[(IS)-4,7-difluor-2,3-dihydro-lH-inden-l-yl]sulfamid, 30) (+)-N-(7-chlor-2,3-dihydro-lH-inden-l-yl)sulfamid, 31) (+)-N-(5-cyano-7-methyl-2,3-dihydro-lH-inden-l-yl)sulfamid, 32) (-)-N-(5-cyano-7-methyl-2,3-dihydro-lH-inden-l-yl)sulfamid, 33) N-[ (IS)-7-chlor-5-fluor-2,3-dihydro-lH-inden-l-yl]sulfamid og 34) (-)-N-(4,6,7-trifluor-2,3-dihydro-lH-inden-l-yl)sulfamid.
2. Forbindelse eller farmaceutisk acceptabelt salt deraf ifølge krav 1, som er valgt fra følgende gruppe: 1) N-[ (IS)-2,2,5,7-tetrafluor-2,3-dihydro-lH-inden-l-yl]sulfamid, 2) N-[(13)-2,2,4,7-tetrafluor-2,3-dihydro-lH-inden-l-yl]sulfamid, 3) (-)-N-(7-chlor-2,2,5-trifluor-2,3-dihydro-lH-inden-l-yl)sulfamid, 4) (-)-N- (7-chlor-2,2-difluor-2,3-dihydro-lH-inden-l-yl)sulfamid, 5) N-[ (IS)-2,2-difluor-7-methyl-2,3-dihydro-lH-inden-l-yl]sulfamid, 6) N-[(IS)-2,2,5-trifluor-7-methyl-2,3-dihydro-lH-inden-l-yl]sulfamid, 7) N-[(IS)-4,7-difluor-2,3-dihydro-lH-inden-l-yl]sulfamid, 8) N-[ (IS)-7-chlor-5-fluor-2,3-dihydro-lH-inden-l-yl]sulfamid og 9) (-)-N-(4,6,7-trifluor-2,3-dihydro-lH-inden-l-yl)sulfamid.
3. Forbindelse ifølge krav 1, som er N-[ (IS)-2,2,5-trifluor- 7-methyl-2,3-dihydro-lH-inden-l-yl]sulfamid eller et farmaceutisk acceptabelt salt deraf.
4. Forbindelse ifølge krav 1, som er (-)-N-(7-chlor-2,2,5- trifluor-2,3-dihydro-lH-inden-l-yl)sulfamid eller et farmaceutisk acceptabelt salt deraf.
5. Forbindelse ifølge krav 1, som er N-[ (IS)-2,2,5,7- tetrafluor-2,3-dihydro-lH-inden-l-yl]sulfamid eller et farmaceutisk acceptabelt salt deraf.
6. Forbindelse ifølge krav 1, som er N-[(IS)-2,2-difluor-7- methyl-2,3-dihydro-lH-inden-l-yl]sulfamid eller et farmaceutisk acceptabelt salt deraf.
7. Forbindelse ifølge krav 1, som er N-[ (IS)-4,7-difluor- 2,3-dihydro-lH-inden-l-yl]sulfamid eller et farmaceutisk acceptabelt salt deraf.
8. Farmaceutisk sammensætning til behandling af epilepsi, hvilken sammensætning omfatter forbindelsen eller det farmaceutisk acceptable salt deraf ifølge et hvilket som helst af kravene 1-7.
9. Forbindelse ifølge et hvilket som helst af kravene 1-7 eller den farmaceutiske sammensætning til anvendelse ved en fremgangsmåde til behandling af epilepsi.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662626P | 2012-06-21 | 2012-06-21 | |
| US201261709737P | 2012-10-04 | 2012-10-04 | |
| US201361751331P | 2013-01-11 | 2013-01-11 | |
| PCT/JP2013/066623 WO2013191144A1 (ja) | 2012-06-21 | 2013-06-17 | 新規インダンスルファミド誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2865663T3 true DK2865663T3 (da) | 2017-06-19 |
Family
ID=49768740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13807707.8T DK2865663T3 (da) | 2012-06-21 | 2013-06-17 | Hidtil ukendte indansulfamidderivater |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9018260B2 (da) |
| EP (1) | EP2865663B1 (da) |
| JP (1) | JP5883135B2 (da) |
| KR (1) | KR101951519B1 (da) |
| CN (1) | CN104395285B (da) |
| AR (1) | AR091506A1 (da) |
| AU (1) | AU2013278450B2 (da) |
| BR (1) | BR112014031565B1 (da) |
| CA (1) | CA2877097C (da) |
| CL (1) | CL2014003429A1 (da) |
| CY (1) | CY1119171T1 (da) |
| DK (1) | DK2865663T3 (da) |
| ES (1) | ES2628374T3 (da) |
| HR (1) | HRP20170863T1 (da) |
| HU (1) | HUE033583T2 (da) |
| IL (1) | IL236295A (da) |
| JO (1) | JO3263B1 (da) |
| LT (1) | LT2865663T (da) |
| ME (1) | ME02753B (da) |
| MX (1) | MX355261B (da) |
| MY (1) | MY169073A (da) |
| NZ (1) | NZ702974A (da) |
| PE (1) | PE20150284A1 (da) |
| PH (1) | PH12014502805A1 (da) |
| PL (1) | PL2865663T3 (da) |
| PT (1) | PT2865663T (da) |
| RS (1) | RS56073B1 (da) |
| RU (1) | RU2619937C2 (da) |
| SG (1) | SG11201408359PA (da) |
| SI (1) | SI2865663T1 (da) |
| SM (1) | SMT201700287T1 (da) |
| TW (1) | TWI597263B (da) |
| WO (1) | WO2013191144A1 (da) |
| ZA (1) | ZA201409248B (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016002974A (es) | 2013-09-09 | 2016-06-02 | Peloton Therapeutics Inc | Eteres de arilo y sus usos. |
| ES2737148T3 (es) | 2013-12-16 | 2020-01-10 | Peloton Therapeutics Inc | Análogos de sulfona y sulfoximina cíclicos y usos de los mismos |
| CN105792821B (zh) * | 2013-12-19 | 2018-05-04 | 卫材R&D管理有限公司 | 包含1-茚满硫酰胺衍生物的疼痛治疗剂和/或预防剂 |
| EP3268362B1 (en) | 2015-03-11 | 2021-10-20 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
| WO2016145045A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions for use in treating glioblastoma |
| EP3267792A4 (en) * | 2015-03-11 | 2018-09-26 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
| US10807948B2 (en) | 2015-03-11 | 2020-10-20 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
| WO2016168510A1 (en) | 2015-04-17 | 2016-10-20 | Peloton Therapeutics, Inc. | Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
| US9796697B2 (en) | 2015-06-12 | 2017-10-24 | Peloton Therapeutics, Inc. | Tricyclic inhibitors of HIF-2-alpha and uses thereof |
| BR112020017835A2 (pt) | 2018-03-20 | 2020-12-29 | Eisai R&D Management Co., Ltd. | Agente de tratamento de epilepsia |
| JP2024026905A (ja) * | 2020-11-25 | 2024-02-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | てんかん治療剤 |
| EP4480474A4 (en) * | 2022-04-27 | 2026-02-25 | Eisai R&D Man Co Ltd | Pharmaceutical composition for the treatment of Parkinson's disease |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3383414A (en) * | 1964-08-26 | 1968-05-14 | Sandoz Ag | Benzocycloalkyl sulfamides |
| US3709677A (en) | 1969-06-25 | 1973-01-09 | Sandoz Ag | N-substituted sulfamoyl compounds useful as herbicides |
| US6958416B2 (en) * | 2001-06-26 | 2005-10-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Valproyltaurinamide derivatives as anticonvulsant amd CNS active agents |
| TW200307539A (en) * | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| MX2007002309A (es) * | 2004-08-24 | 2007-10-08 | Johnson & Johnson | Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos. |
| US20070155823A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
| CN100572365C (zh) * | 2006-01-26 | 2009-12-23 | 全哲山 | 用作抗癫痫药的1,2,4-三唑并[4,3-a]喹啉-1-酮衍生物及其可药用盐 |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| AR070949A1 (es) * | 2007-10-19 | 2010-05-19 | Solvay Pharm Gmbh | Compuestos derivados de sulfamato de uso medico, medicamentos y composiciones farmaceuticas que los comprenden, procedimientos para preparar estos compuestos y su uso |
| TW201012803A (en) * | 2008-06-06 | 2010-04-01 | Organon Nv | Heterocyclic derivatives |
| EP2417101B1 (en) * | 2009-04-09 | 2013-10-23 | Merck Sharp & Dohme B.V. | Indane derivatives |
| RS61829B1 (sr) | 2009-11-13 | 2021-06-30 | Receptos Llc | Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze |
| AU2010319982B2 (en) | 2009-11-13 | 2016-02-04 | Receptos Llc | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| US20120302546A1 (en) * | 2010-02-04 | 2012-11-29 | Fox Chase Chemical Diversity Center, Inc. | Novel sulfamides exhibiting neuroprotective action and methods for use thereof |
| US20120077814A1 (en) * | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
-
2013
- 2013-06-17 DK DK13807707.8T patent/DK2865663T3/da active
- 2013-06-17 SM SM20170287T patent/SMT201700287T1/it unknown
- 2013-06-17 RU RU2014151013A patent/RU2619937C2/ru active
- 2013-06-17 ME MEP-2017-128A patent/ME02753B/me unknown
- 2013-06-17 SI SI201330677A patent/SI2865663T1/sl unknown
- 2013-06-17 NZ NZ702974A patent/NZ702974A/en unknown
- 2013-06-17 LT LTEP13807707.8T patent/LT2865663T/lt unknown
- 2013-06-17 AU AU2013278450A patent/AU2013278450B2/en active Active
- 2013-06-17 EP EP13807707.8A patent/EP2865663B1/en active Active
- 2013-06-17 MX MX2014015492A patent/MX355261B/es active IP Right Grant
- 2013-06-17 PL PL13807707T patent/PL2865663T3/pl unknown
- 2013-06-17 CA CA2877097A patent/CA2877097C/en active Active
- 2013-06-17 MY MYPI2014703797A patent/MY169073A/en unknown
- 2013-06-17 HR HRP20170863TT patent/HRP20170863T1/hr unknown
- 2013-06-17 RS RS20170587A patent/RS56073B1/sr unknown
- 2013-06-17 PT PT138077078T patent/PT2865663T/pt unknown
- 2013-06-17 WO PCT/JP2013/066623 patent/WO2013191144A1/ja not_active Ceased
- 2013-06-17 US US14/370,633 patent/US9018260B2/en active Active
- 2013-06-17 HU HUE13807707A patent/HUE033583T2/hu unknown
- 2013-06-17 CN CN201380031833.8A patent/CN104395285B/zh active Active
- 2013-06-17 PE PE2014002429A patent/PE20150284A1/es active IP Right Grant
- 2013-06-17 BR BR112014031565-5A patent/BR112014031565B1/pt active IP Right Grant
- 2013-06-17 ES ES13807707.8T patent/ES2628374T3/es active Active
- 2013-06-17 KR KR1020147035140A patent/KR101951519B1/ko active Active
- 2013-06-17 SG SG11201408359PA patent/SG11201408359PA/en unknown
- 2013-06-17 JP JP2014521462A patent/JP5883135B2/ja active Active
- 2013-06-18 JO JOP/2013/0184A patent/JO3263B1/ar active
- 2013-06-19 AR ARP130102174 patent/AR091506A1/es active IP Right Grant
- 2013-06-21 TW TW102122236A patent/TWI597263B/zh active
-
2014
- 2014-12-15 ZA ZA2014/09248A patent/ZA201409248B/en unknown
- 2014-12-15 IL IL236295A patent/IL236295A/en active IP Right Grant
- 2014-12-17 PH PH12014502805A patent/PH12014502805A1/en unknown
- 2014-12-17 CL CL2014003429A patent/CL2014003429A1/es unknown
-
2017
- 2017-06-15 CY CY20171100633T patent/CY1119171T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2865663T3 (da) | Hidtil ukendte indansulfamidderivater | |
| CN111836798B (zh) | 氯胺酮的前药、其组合物和用途 | |
| EP3807251B1 (en) | Phenyl and pyridinyl substituted imidazoles as modulators of roryt | |
| KR102250214B1 (ko) | 1-인단설파미드 유도체를 포함하는 통증에 대한 치료제 및/또는 예방제 | |
| EP3515913B1 (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| RU2735277C2 (ru) | 3,3-дифторпиперидинкарбаматные гетероциклические соединения в качестве антагонистов nr2b nmda-рецептора | |
| Chen et al. | Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors | |
| EP2382206A2 (en) | Compounds and methods for the treatment of pain and other diseases | |
| EA020010B1 (ru) | БИЦИКЛИЧЕСКИЕ ТИАЗОЛЫ В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5 РЕЦЕПТОРОВ | |
| EP3915994B9 (en) | Compounds and compositions for inducing chondrogenesis | |
| EP3353163B1 (en) | 2,3,4,5-tetrahydropyridin-6-amine derivatives | |
| JP4728640B2 (ja) | ニューロトロフィン関連疾患の治療用医薬組成物 | |
| HK1207363B (en) | Novel indanesulfamide derivative | |
| JP7798891B2 (ja) | Ｄ１陽性アロステリック調節因子としての置換テトラヒドロイソキノリン誘導体 | |
| EP4324835A1 (en) | Pyrimidinone derivative and preparation method therefor, pharmaceutical composition, and use | |
| UA80190C2 (en) | Sustituted indoline and indole derivatives | |
| HK40055222B (en) | Compounds and compositions for inducing chondrogenesis | |
| Beguin | Synthesis of functionalized amino acids (FAA) analogues and studies toward the FAA site of action for the control of convulsive disorders | |
| HK40007808B (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| UA79666C2 (en) | 1,2,4-triaminobenzene derivatives suitable for the treatment of the central nervous system disorders |